182 related articles for article (PubMed ID: 36614890)
1. The Impact of b/tsDMARD Dose Reduction on Chronic Hepatitis B in Rheumatoid Arthritis Patients: A Two-Center Long-Term Safety Analysis.
Chen DY; Chen HH; Chang SH; Chen YM; Huang PH; Hsieh CW; Lan JL; Tang KT
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614890
[TBL] [Abstract][Full Text] [Related]
2. HBV reactivation in HBsAg-/HBcAb+ rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs.
Kuo MH; Tseng CW; Ko PH; Wang ST; Lu MC; Tung CH; Tseng KC; Huang KY; Lee CH; Lai NS
Liver Int; 2024 Feb; 44(2):497-507. PubMed ID: 38010984
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
4. Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis.
Hong X; Xiao Y; Xu L; Liu L; Mo H; Mo H
Immun Inflamm Dis; 2023 Feb; 11(2):e780. PubMed ID: 36840482
[TBL] [Abstract][Full Text] [Related]
5. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib.
Wang ST; Tseng CW; Hsu CW; Tung CH; Huang KY; Lu MC; Lai NS
Int J Rheum Dis; 2021 Nov; 24(11):1362-1369. PubMed ID: 34506078
[TBL] [Abstract][Full Text] [Related]
6. Incidence of dementia in patients with rheumatoid arthritis and association with disease modifying anti-rheumatic drugs - Analysis of a national claims database.
Sattui SE; Navarro-Millan I; Xie F; Rajan M; Yun H; Curtis JR
Semin Arthritis Rheum; 2022 Dec; 57():152083. PubMed ID: 36155968
[TBL] [Abstract][Full Text] [Related]
7. Paradigm guiding to tapering or discontinuation of biologic and targeted synthetic disease-modifying antirheumatic drugs in the treatment of patients with rheumatoid arthritis: Results from a local prospective study.
Kaban N; Harman H
Int J Rheum Dis; 2023 Apr; 26(4):689-698. PubMed ID: 36807751
[TBL] [Abstract][Full Text] [Related]
8. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Chiu YM; Chen DY
Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
[No Abstract] [Full Text] [Related]
9. Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis.
Lee BW; Lee JJ; Kim WU
Korean J Intern Med; 2024 May; ():. PubMed ID: 38798047
[TBL] [Abstract][Full Text] [Related]
10. Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia.
Fletcher A; Lassere M; March L; Hill C; Barrett C; Carroll G; Buchbinder R
Rheumatology (Oxford); 2022 Oct; 61(10):3939-3951. PubMed ID: 35094044
[TBL] [Abstract][Full Text] [Related]
11. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
Watanabe T; Fukae J; Fukaya S; Sawamukai N; Isobe M; Matsuhashi M; Shimizu M; Akikawa K; Tanimura K; Atsumi T; Koike T
Int J Rheum Dis; 2019 Apr; 22(4):574-582. PubMed ID: 30338649
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.
Tamori A; Koike T; Goto H; Wakitani S; Tada M; Morikawa H; Enomoto M; Inaba M; Nakatani T; Hino M; Kawada N
J Gastroenterol; 2011 Apr; 46(4):556-64. PubMed ID: 21246383
[TBL] [Abstract][Full Text] [Related]
13. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
Nakamura J; Nagashima T; Nagatani K; Yoshio T; Iwamoto M; Minota S
Int J Rheum Dis; 2016 May; 19(5):470-5. PubMed ID: 24698305
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.
Chung SJ; Kim JK; Park MC; Park YB; Lee SK
J Rheumatol; 2009 Nov; 36(11):2416-20. PubMed ID: 19797507
[TBL] [Abstract][Full Text] [Related]
15. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment.
Chen MH; Chen MH; Liu CY; Tsai CY; Huang DF; Lin HY; Lee MH; Huang YH
J Infect Dis; 2017 Feb; 215(4):566-573. PubMed ID: 28011918
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs.
Tan J; Zhou J; Zhao P; Wei J
Clin Rheumatol; 2012 Aug; 31(8):1169-75. PubMed ID: 22544263
[TBL] [Abstract][Full Text] [Related]
18. Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.
Chiu YM; Lai MS; Chan KA
PLoS One; 2018; 13(4):e0196210. PubMed ID: 29694398
[TBL] [Abstract][Full Text] [Related]
19. [Investigation of the risk of hepatitis B virus reactivation in arthritis patients undergoing anti-tumour necrosis factor alpha therapy].
Jin D; Tie N; Liu J; Zhao L; Hao D; Zhao Y
Zhonghua Nei Ke Za Zhi; 2015 Apr; 54(4):313-6. PubMed ID: 26268059
[TBL] [Abstract][Full Text] [Related]
20. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs.
Mori S
Mod Rheumatol; 2011 Dec; 21(6):621-7. PubMed ID: 21528424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
